Search results
U.S. FDA panel backs expanded use of Alnylam's gene silencing drug
Reuters via Yahoo News· 9 months agoThe FDA panel voted 9 to 3 that the benefits of the drug, patisiran, outweigh its risks for treating...
How A First-Ever In Gene Silencing Catapulted Avidity Biosciences Into The Stratosphere
Investor's Business Daily· 1 year agoAvidity Biosciences unveiled "compelling" results from a muscular dystrophy study Wednesday, leading...
Role of Genes in hATTR Amyloidosis
Verywell Health via Yahoo News· 4 months agoAn inherited disease caused by abnormal protein buildup Medically reviewed by Kashif J. Piracha, MD Hereditary ATTR amyloidosis (hATTR amyloidosis) is a...
Genetics, Alzheimer's And AI — Why 2023 Could Be The Year For Biotech Stocks
Investor's Business Daily· 1 year agoIf there's one overarching theme that investors in biotech stocks should pay attention to in 2023,...
UPDATE 2-Alnylam's gene-silencing drug cuts blood pressure in mid-stage trial
Reuters via Yahoo Finance· 9 months agoAlnylam Pharmaceuticals said on Thursday its experimental gene-silencing therapy helped significantly reduce high blood pressure in patients in a mid-stage trial. The therapy, zilebesiran, helped ...
Sperm from older rats passes on fewer active genes to offspring because of epigenetic changes
The Conversation via Yahoo News· 4 months agoIf the same mechanism exists in humans, it may explain health differences in children conceived by...
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
Motley Fool· 1 year agoBiotech stocks got pummeled in 2022. Valuations across the small- and mid-cap biotech landscape...
Voyager Therapeutics Prioritizes Pipeline With Cash Runway Into 2024
Benzinga via Yahoo Finance· 2 years agoVoyager Therapeutics Inc (NASDAQ: VYGR) unveiled its prioritized therapeutic pipeline focusing on...
Scientists finally decode how the ovary’s egg-production capacity changes with age
The Independent via Yahoo News· 2 years agoScientists have decoded the biological mechanisms in mice governing the ovary’s capacity to provide...
Arrowhead Pharmaceuticals Inc Reports Fiscal 2023 Year-End Results
GuruFocus.com via Yahoo Finance· 6 months agoArrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced a net loss of $205.3 million for the fiscal...